Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totaling 101,076 shares, a decline of 19.4% from the March 31st total of 125,433 shares. Based on an average daily volume of 34,678 shares, the days-to-cover ratio is presently 2.9 days. Currently, 1.4% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mustang Bio in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Mustang Bio

A hedge fund recently bought a new stake in Mustang Bio stock. DRW Securities LLC purchased a new position in Mustang Bio, Inc. (NASDAQ:MBIO) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned about 1.01% of Mustang Bio at the end of the most recent reporting period. 9.95% of the stock is currently owned by hedge funds and other institutional investors.

Mustang Bio Stock Up 1.8%

Shares of NASDAQ:MBIO traded up $0.01 on Friday, reaching $0.75. The company had a trading volume of 34,545 shares, compared to its average volume of 35,460. Mustang Bio has a twelve month low of $0.53 and a twelve month high of $7.00. The stock has a 50-day moving average price of $0.83 and a 200 day moving average price of $1.05. The stock has a market capitalization of $5.72 million, a P/E ratio of -1.93 and a beta of 2.18.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.